Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
Holding ETNB?
Track your performance easily
ETNB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.15 - $16.63
Previous CloseN/A
Volume91.20K
Average Volume (3M)1.18M
Market Cap
$738.42M
Enterprise Value$406.15M
Total Cash (Recent Filing)$11.23M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Mar 19, 2025EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.91
Shares Outstanding117,582,220
10 Day Avg. Volume859,648
30 Day Avg. Volume1,176,867
Standard Deviation0.24
R-Squared0.05
Alpha-0.00155
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$26.60Price Target Upside336.07% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
89bio News
PremiumCompany Announcements
89bio Strengthens Leadership Retention with New RSUs
PremiumCompany Announcements
89Bio Inc. Reports Q3 2024 Financial Results
Ownership Overview
13.23% Insiders
12.18% Mutual Funds
0.50% Other Institutional Investors
63.58% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ETNB FAQ
What was 89bio’s price range in the past 12 months?
89bio lowest stock price was $6.15 and its highest was $16.63 in the past 12 months.
What is 89bio’s market cap?
89bio’s market cap is $738.42M.
When is 89bio’s upcoming earnings report date?
89bio’s upcoming earnings report date is Mar 19, 2025 which is in 60 days.
How were 89bio’s earnings last quarter?
89bio released its earnings results on Nov 07, 2024. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$0.624 by -$0.766.
Is 89bio overvalued?
According to Wall Street analysts 89bio’s price is currently Undervalued.
Does 89bio pay dividends?
89bio does not currently pay dividends.
What is 89bio’s EPS estimate?
89bio’s EPS estimate is -0.76.
How many shares outstanding does 89bio have?
89bio has 117,582,220 shares outstanding.
What happened to 89bio’s price movement after its last earnings report?
89bio reported an EPS of -$1.39 in its last earnings report, missing expectations of -$0.624. Following the earnings report the stock price went up 4.92%.
Which hedge fund is a major shareholder of 89bio?
Among the largest hedge funds holding 89bio’s share is RA Capital Management. It holds 89bio’s shares valued at 105M.
---
89bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$26.60 (336.07% Upside)
$26.60 (336.07% Upside)
Blogger Sentiment
Bullish
ETNB Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 53.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $202.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.94%
12-Months-Change
Fundamentals
Return on Equity
-73.31%
Trailing 12-Months
Asset Growth
-0.39%
Trailing 12-Months
Company Description
89bio
89bio, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of innovative therapies for nonalcoholic steatohepatitis (NASH), liver and cardio-metabolic diseases. The company was founded on January 01, 2018 and is headquartered in San Francisco, CA.
---
ETNB Stock 12 Month Forecast
Average Price Target
$26.60
▲(336.07% Upside)
Technical Analysis
Terns Pharmaceuticals
―
EyePoint Pharmaceuticals
―
Akero Therapeutics
―
Viking Therapeutics
―
Madrigal Pharmaceuticals
―
Regeneron
―
Best Analysts Covering ETNB
1 Year
1 Year Success Rate
7/17 ratings generated profit
1 Year Average Return
+77.50%
reiterated a buy rating 8 months ago
Copying Justin Zelin's trades and holding each position for 1 Year would result in 41.18% of your transactions generating a profit, with an average return of +77.50% per trade.
---